Table 1.
Baseline patient characteristics.a
| Variable | ARA 290 | Placebo |
|---|---|---|
| Subjects | 24 | 24 |
| Males/females | 18/6 | 12/12 |
| Weight (kg) | 92.2 ± 3.8 | 91.7 ± 2.7 |
| Age | 63.0 ± 1.5 | 63.8 ± 1.4 |
| Height (cm) | 175.3 ± 1.8 | 171.0 ± 1.6 |
| BMI | 29.9 ± 1.0 | 31.4 ± 0.8 |
| ARA 290 dose (mcg/kg) | 45.0 ± 1.9 | 0 |
| ARA 290 dose (mg/ m2) | 1.9 ± 0.05 | 0 |
| hs-CRPb | 3.35 ± 0.86 | 3.73 ± 1.17 |
| Hb A1c (%; mmol/mol)c | 7.3 ± 0.4; 55.8 ± 4.4 [5.4%, 6.6%, 12.3%] | 6.9 ± 0.2; 51.7 ± 1.9 [5.8%, 6.7%, 9.3%] |
| Cholesterol (mmol/L) | 4.57 ± 0.18 | 4.59 ± 0.15 |
| HDL (mmol/L) | 1.22 ± 0.09 | 1.35 ± 0.08 |
| Triglycerides (mmol/L) | 2.35 ± 0.25 | 2.30 ± 0.27 |
| SFNSL total score | 24.8 ± 2.5 [3, 25, 52] | 21.3 ± 1.7 [7, 21, 38] |
| RAND-36 | ||
| NPSI total score | 17.0 ± 2.0 [0, 16.5, 33.3] | 21.7 ± 2.0 [4.5, 22.8, 37.5] |
| PainDetect total score | 18.0 ± 1.4 [6, 20, 27] | 18.0 ± 1.3 [6, 20, 28] |
| 6MWT (m) | 410.3 ± 17.4 | 447.8 ± 19.6 |
| 6MWT predicted (m)c | 656.0 ± 13.8 | 618.4 ± 13.6 |
| CNFD (number/mm2) | 24.8 ± 1.4 | 24.1 ± 1.7 |
a
Values correspond to number or mean ± SEM. Values within brackets refer to the range as: minimum, median, maximum.
b
hs-CRP, high-sensitivity C-reactive protein.
c
For each group, n = 21. Only subjects with A1c values at baseline, d 28 and d 56 included (n = 42).
c
Calculated from Troosters et al. (35).